Frommhold H
Universitätsklinik für Strahlentherapie Innsbruck.
Rontgenblatter. 1988 Mar;41(3):108-12.
Current radiotherapy is effective both in treating the non-small cell bronchial carcinoma and the small-cell anaplastic carcinoma. The spectrum of radio-oncologic methods requires on-target determination of indication. Curative treatment of non-small cell bronchial carcinoma may yield 5-year survival rates of 11% in case of radiotherapy; if onset of treatment is early, this rate may increase to 20%. Even in elderly patients (70-75%) the results are by no means inferior compared to younger patients. Adjuvant postoperative radiotherapy is indicated in N2 cases. Palliative radiotherapy is of undisputed value in non-small cell bronchial carcinomas. For treating the non-small cell anaplastic bronchial carcinoma, radiotherapy is an essential part of a multimodal interdisciplinary therapeutic concept. In combination therapy it ensures complete remission, reduces the relapse rate and results in remarkable long-term remissions because of its essential target areas in the region of the primary tumour and the cerebrum together with chemotherapy and surgery, and hence in an improvement of the survival time.
目前的放射疗法在治疗非小细胞支气管癌和小细胞间变性癌方面均有效。放射肿瘤学方法的范围需要对适应症进行精准确定。对于非小细胞支气管癌的根治性治疗，放射治疗的5年生存率可能为11%；如果治疗开始得早，这一比率可能会提高到20%。即使在老年患者中（70 - 75%），结果与年轻患者相比也绝不逊色。N2病例需进行术后辅助放疗。姑息性放疗在非小细胞支气管癌中具有无可争议的价值。对于治疗非小细胞间变性支气管癌，放射治疗是多模式跨学科治疗理念的重要组成部分。在联合治疗中，由于其在原发性肿瘤区域和大脑区域的关键靶区，与化疗和手术一起，它能确保完全缓解，降低复发率，并带来显著的长期缓解，从而延长生存时间。
